KRAS and neoplasm: There was no correlation between mutations and clinicopathologic features, including age, gender, tumor location, type of resection, circumferential margin (CRM), differentiation grade, lymph node and TNM stage.We also investigated whether KRAS, BRAF or PIK3CA mutations may confer radioresistance and reduced response to CRT.